The grant is from the Eunice Kennedy Shriver National Institute of Child Health & Human Development.
PLx Pharma and UTHealth are working to reduce the GI toxicity of NSAIDs by formulating this family of drugs with a natural lipid named phosphatidylcholine.
PLx Pharma president Ron Zimmerman said the product is being developed to meet a serious unmet need for the compelling patient population.